Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy
Background In order to analyze the clinical activity and cost-effectiveness of granulocyte colony-stimulating factors (G-CSF), the prophylactic usage of G-CSF in patients treated with a single chemotherapy regimen during early courses was prospectively evaluated. Methods Thirty patients with newly d...
Saved in:
| Published in | International journal of clinical oncology Vol. 16; no. 2; pp. 118 - 124 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Japan
Springer Japan
01.04.2011
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background
In order to analyze the clinical activity and cost-effectiveness of granulocyte colony-stimulating factors (G-CSF), the prophylactic usage of G-CSF in patients treated with a single chemotherapy regimen during early courses was prospectively evaluated.
Methods
Thirty patients with newly diagnosed non-Hodgkin lymphoma (NHL) treated with the first course of an R-CHOP regimen were enrolled randomly. After treatment with the first course of chemotherapy, a daily dose of G-CSF (lenograstim, 100 μg) was administered to half (15 cases) of the patients, and a dose of G-CSF (100 μg) was administered every other day to the other half of the patients when leukocytopenia (<1.5 × 10
9
/L) and/or neutropenia (<0.5 × 10
9
/L) occurred. Changes in leukocyte and neutrophil counts, prophylaxis, febrile neutropenia (FN) events, and cost performance between the two groups were analyzed.
Results
No significant difference between the two groups was observed in recoveries of leukocyte and neutrophil counts and evidence of FN. The only difference was the total cost of G-CSF.
Conclusion
We concluded that every-other-day use of G-CSF was as clinically effective for the prophylaxis of FN as the daily use of G-CSF, and economically speaking, the administration of G-CSF every other day should be more beneficial for patients with NHL during early courses of R-CHOP chemotherapy. |
|---|---|
| AbstractList | In order to analyze the clinical activity and cost-effectiveness of granulocyte colony-stimulating factors (G-CSF), the prophylactic usage of G-CSF in patients treated with a single chemotherapy regimen during early courses was prospectively evaluated.BACKGROUNDIn order to analyze the clinical activity and cost-effectiveness of granulocyte colony-stimulating factors (G-CSF), the prophylactic usage of G-CSF in patients treated with a single chemotherapy regimen during early courses was prospectively evaluated.Thirty patients with newly diagnosed non-Hodgkin lymphoma (NHL) treated with the first course of an R-CHOP regimen were enrolled randomly. After treatment with the first course of chemotherapy, a daily dose of G-CSF (lenograstim, 100 μg) was administered to half (15 cases) of the patients, and a dose of G-CSF (100 μg) was administered every other day to the other half of the patients when leukocytopenia (<1.5 × 10(9)/L) and/or neutropenia (<0.5 × 10(9)/L) occurred. Changes in leukocyte and neutrophil counts, prophylaxis, febrile neutropenia (FN) events, and cost performance between the two groups were analyzed.METHODSThirty patients with newly diagnosed non-Hodgkin lymphoma (NHL) treated with the first course of an R-CHOP regimen were enrolled randomly. After treatment with the first course of chemotherapy, a daily dose of G-CSF (lenograstim, 100 μg) was administered to half (15 cases) of the patients, and a dose of G-CSF (100 μg) was administered every other day to the other half of the patients when leukocytopenia (<1.5 × 10(9)/L) and/or neutropenia (<0.5 × 10(9)/L) occurred. Changes in leukocyte and neutrophil counts, prophylaxis, febrile neutropenia (FN) events, and cost performance between the two groups were analyzed.No significant difference between the two groups was observed in recoveries of leukocyte and neutrophil counts and evidence of FN. The only difference was the total cost of G-CSF.RESULTSNo significant difference between the two groups was observed in recoveries of leukocyte and neutrophil counts and evidence of FN. The only difference was the total cost of G-CSF.We concluded that every-other-day use of G-CSF was as clinically effective for the prophylaxis of FN as the daily use of G-CSF, and economically speaking, the administration of G-CSF every other day should be more beneficial for patients with NHL during early courses of R-CHOP chemotherapy.CONCLUSIONWe concluded that every-other-day use of G-CSF was as clinically effective for the prophylaxis of FN as the daily use of G-CSF, and economically speaking, the administration of G-CSF every other day should be more beneficial for patients with NHL during early courses of R-CHOP chemotherapy. In order to analyze the clinical activity and cost-effectiveness of granulocyte colony-stimulating factors (G-CSF), the prophylactic usage of G-CSF in patients treated with a single chemotherapy regimen during early courses was prospectively evaluated. Thirty patients with newly diagnosed non-Hodgkin lymphoma (NHL) treated with the first course of an R-CHOP regimen were enrolled randomly. After treatment with the first course of chemotherapy, a daily dose of G-CSF (lenograstim, 100 μg) was administered to half (15 cases) of the patients, and a dose of G-CSF (100 μg) was administered every other day to the other half of the patients when leukocytopenia (<1.5 × 10(9)/L) and/or neutropenia (<0.5 × 10(9)/L) occurred. Changes in leukocyte and neutrophil counts, prophylaxis, febrile neutropenia (FN) events, and cost performance between the two groups were analyzed. No significant difference between the two groups was observed in recoveries of leukocyte and neutrophil counts and evidence of FN. The only difference was the total cost of G-CSF. We concluded that every-other-day use of G-CSF was as clinically effective for the prophylaxis of FN as the daily use of G-CSF, and economically speaking, the administration of G-CSF every other day should be more beneficial for patients with NHL during early courses of R-CHOP chemotherapy. Background In order to analyze the clinical activity and cost-effectiveness of granulocyte colony-stimulating factors (G-CSF), the prophylactic usage of G-CSF in patients treated with a single chemotherapy regimen during early courses was prospectively evaluated. Methods Thirty patients with newly diagnosed non-Hodgkin lymphoma (NHL) treated with the first course of an R-CHOP regimen were enrolled randomly. After treatment with the first course of chemotherapy, a daily dose of G-CSF (lenograstim, 100 μg) was administered to half (15 cases) of the patients, and a dose of G-CSF (100 μg) was administered every other day to the other half of the patients when leukocytopenia (<1.5 × 10 9 /L) and/or neutropenia (<0.5 × 10 9 /L) occurred. Changes in leukocyte and neutrophil counts, prophylaxis, febrile neutropenia (FN) events, and cost performance between the two groups were analyzed. Results No significant difference between the two groups was observed in recoveries of leukocyte and neutrophil counts and evidence of FN. The only difference was the total cost of G-CSF. Conclusion We concluded that every-other-day use of G-CSF was as clinically effective for the prophylaxis of FN as the daily use of G-CSF, and economically speaking, the administration of G-CSF every other day should be more beneficial for patients with NHL during early courses of R-CHOP chemotherapy. In order to analyze the clinical activity and cost-effectiveness of granulocyte colony-stimulating factors (G-CSF), the prophylactic usage of G-CSF in patients treated with a single chemotherapy regimen during early courses was prospectively evaluated. Thirty patients with newly diagnosed non-Hodgkin lymphoma (NHL) treated with the first course of an R-CHOP regimen were enrolled randomly. After treatment with the first course of chemotherapy, a daily dose of G-CSF (lenograstim, 100 μg) was administered to half (15 cases) of the patients, and a dose of G-CSF (100 μg) was administered every other day to the other half of the patients when leukocytopenia (<1.5 × 10^sup 9^/L) and/or neutropenia (<0.5 × 10^sup 9^/L) occurred. Changes in leukocyte and neutrophil counts, prophylaxis, febrile neutropenia (FN) events, and cost performance between the two groups were analyzed. No significant difference between the two groups was observed in recoveries of leukocyte and neutrophil counts and evidence of FN. The only difference was the total cost of G-CSF. We concluded that every-other-day use of G-CSF was as clinically effective for the prophylaxis of FN as the daily use of G-CSF, and economically speaking, the administration of G-CSF every other day should be more beneficial for patients with NHL during early courses of R-CHOP chemotherapy.[PUBLICATION ABSTRACT] |
| Author | TAKAOKA Ikue YAKUSHIJIN Yoshihiro AZUMA Taichi SHIKATA Hisaharu HATO Takaaki YAMANOUCHI Jun YASUKAWA Masaki HORIKAWA Tamami TAKEUCHI Kazuhito NARUMI Hiroshi |
| Author_xml | – sequence: 1 givenname: Yoshihiro surname: Yakushijin fullname: Yakushijin, Yoshihiro email: yoshiyak@m.ehime-u.ac.jp organization: Cancer Center of Ehime University Hospital, Ehime University Graduate School of Medicine – sequence: 2 givenname: Hisaharu surname: Shikata fullname: Shikata, Hisaharu organization: Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine – sequence: 3 givenname: Ikue surname: Takaoka fullname: Takaoka, Ikue organization: Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine – sequence: 4 givenname: Tamami surname: Horikawa fullname: Horikawa, Tamami organization: Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine – sequence: 5 givenname: Kazuhito surname: Takeuchi fullname: Takeuchi, Kazuhito organization: Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine – sequence: 6 givenname: Jun surname: Yamanouchi fullname: Yamanouchi, Jun organization: Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine – sequence: 7 givenname: Taichi surname: Azuma fullname: Azuma, Taichi organization: Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine – sequence: 8 givenname: Hiroshi surname: Narumi fullname: Narumi, Hiroshi organization: Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine – sequence: 9 givenname: Takaaki surname: Hato fullname: Hato, Takaaki organization: Division of Blood Transfusion and Cell Therapy, Ehime University Graduate School of Medicine – sequence: 10 givenname: Masaki surname: Yasukawa fullname: Yasukawa, Masaki organization: Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine |
| BackLink | https://cir.nii.ac.jp/crid/1573105974853107584$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/20924633$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kctq3jAQhU1JaS7tA3RTRCl05VZXS16W0BsEumnWQpbHfxRk6a8kh_ht-qiVcUIhiyw0msX5hjNnzpuTEAM0zVuCPxGM5edMMOGyxQTXx3h7_6I5I5zJVkpJT2rPOGn7jorT5jznW4yJ7AR91ZxS3FPeMXbW_L3O5gAoTuiQTFh8tGsBZKOPYW1zcfPiTXHhgCZjS0wI7iCtiKLRrBm5jKx3wVnj_YqWDNPikQlj5XNpYZrAFncHaKrgBENyHlCApaR4hOAMGpe0jQaTKm7jkjLkzYq9gTmWG0jmuL5uXk7GZ3jz8F8019--_r780V79-v7z8stVa7nqS6v4wLGqSxGQprcCYFRqHKcO-s50Q42oU4qAYkSMVCgLEveSC8OVHMg4CHbRfNznHlP8s0AuenbZgvcmQFyyVh2hWNT8qvL9E-VttR6quSrCXNCesSp69yBahhlGfUxuNmnVj8lXgdwFNsWcE0zaulKjjqEk47wmWG831vuNdV1AbzfW95UkT8jH4c8xdGfycYsc0n_Pz0Efdig4V91tlQjJCBY1OiVqI4Xi7B-DRcXh |
| CitedBy_id | crossref_primary_10_1016_j_clinthera_2014_06_034 crossref_primary_10_1016_j_transci_2013_05_026 crossref_primary_10_1007_s10147_013_0523_z crossref_primary_10_1111_jep_12597 crossref_primary_10_4103_ijh_ijh_37_21 crossref_primary_10_1038_s41598_017_04495_x |
| Cites_doi | 10.1046/j.1365-2141.1997.2393053.x 10.1093/infdis/163.3.579 10.2165/00003495-200059030-00017 10.1056/NEJM199207023270106 10.1002/ajh.21206 10.1200/JCO.2006.06.4451 10.1016/j.clinthera.2009.05.003 10.1200/JCO.20.3.727 10.1185/030079903125002531 10.1016/0161-5890(90)90060-D 10.1634/theoncologist.12-12-1416 10.1200/JCO.2004.03.213 10.1185/030079907X219599 10.1182/blood.V82.11.3265.3265 10.1182/blood.V88.6.1907.bloodjournal8861907 10.2165/00044011-200929080-00001 10.1093/annonc/mdg019 |
| ContentType | Journal Article |
| Copyright | Japan Society of Clinical Oncology 2010 Japan Society of Clinical Oncology 2011 |
| Copyright_xml | – notice: Japan Society of Clinical Oncology 2010 – notice: Japan Society of Clinical Oncology 2011 |
| DBID | RYH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 K9. M0S M1P M2O MBDVC PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 |
| DOI | 10.1007/s10147-010-0134-x |
| DatabaseName | CiNii Complete CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Research Library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Research Library Prep |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1437-7772 |
| EndPage | 124 |
| ExternalDocumentID | 2312922021 20924633 10_1007_s10147_010_0134_x 10029366407 |
| Genre | Randomized Controlled Trial Journal Article |
| GroupedDBID | --- -~C .55 .86 .VR 06C 06D 0R~ 0VY 1N0 1SB 203 29J 29~ 2J2 2JN 2JY 2KG 2LR 2VQ 2~H 30V 36B 4.4 406 408 409 40D 40E 53G 5GY 5VS 67Z 6NX 7X7 88E 8AO 8C1 8FI 8FJ 8G5 8TC 8UJ 95- 95. 95~ 96X AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAPKM AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBRH ABBXA ABDBE ABDZT ABECU ABFSG ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACSNA ACSTC ACZOJ ADBBV ADHHG ADHIR ADHKG ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AEZWR AFBBN AFDZB AFHIU AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGQPQ AGRTI AGWIL AGWZB AGYKE AHBYD AHIZS AHMBA AHPBZ AHSBF AHWEU AHYZX AIAKS AIGIU AIIXL AILAN AITGF AIXLP AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG ATHPR AVWKF AXYYD AYFIA AZFZN AZQEC B-. BA0 BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 DWQXO EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ7 GQ8 GUQSH GXS HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH LAS LLZTM M1P M2O M4Y MA- N2Q N9A NB0 NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PHGZM PHGZT PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV ROL RPX RRX RSV RYH S16 S27 S37 S3B SAP SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 X7M YLTOR Z45 ZMTXR ZOVNA ~A9 ~EX -53 -5E -5G -BR -EM -Y2 2.D 28- 2P1 3V. 5QI AAAVM ACUDM ADINQ AEFIE AFEXP AGGDS AHAVH BBWZM EBD GQ6 GRRUI H13 IHE KOW NDZJH R4E RNI RZK S1Z S26 S28 SCLPG SDE T16 Z7U Z82 Z83 Z87 Z8O Z8V Z91 AAYXX AFOHR CITATION ABRTQ CGR CUY CVF ECM EIF NPM PJZUB PPXIY 7TO 7XB 8FK H94 K9. MBDVC PKEHL PQEST PQUKI PRINS PUEGO Q9U 7X8 |
| ID | FETCH-LOGICAL-c489t-84b4082461e7a9c5eed88ddf6e96a6b0106881e8315d258ce709745a487b1db53 |
| IEDL.DBID | 7X7 |
| ISSN | 1341-9625 1437-7772 |
| IngestDate | Mon Jul 21 09:55:22 EDT 2025 Sat Aug 23 13:27:41 EDT 2025 Mon Jul 21 05:51:00 EDT 2025 Thu Apr 24 23:11:49 EDT 2025 Tue Jul 01 02:34:33 EDT 2025 Fri Feb 21 02:33:39 EST 2025 Fri Jun 27 00:58:27 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Granulocyte colony-stimulating factors (G-CSF) Cost-benefit R-CHOP Non-Hodgkin lymphoma (NHL) Febrile neutropenia (FN) |
| Language | English |
| License | http://www.springer.com/tdm |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c489t-84b4082461e7a9c5eed88ddf6e96a6b0106881e8315d258ce709745a487b1db53 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23 ObjectType-Undefined-3 |
| PMID | 20924633 |
| PQID | 860452933 |
| PQPubID | 43390 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_861205765 proquest_journals_860452933 pubmed_primary_20924633 crossref_citationtrail_10_1007_s10147_010_0134_x crossref_primary_10_1007_s10147_010_0134_x springer_journals_10_1007_s10147_010_0134_x nii_cinii_1573105974853107584 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2011-04-01 |
| PublicationDateYYYYMMDD | 2011-04-01 |
| PublicationDate_xml | – month: 04 year: 2011 text: 2011-04-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan – name: Tokyo |
| PublicationTitle | International journal of clinical oncology |
| PublicationTitleAbbrev | Int J Clin Oncol |
| PublicationTitleAlternate | Int J Clin Oncol |
| PublicationYear | 2011 |
| Publisher | Springer Japan Springer Nature B.V |
| Publisher_xml | – name: Springer Japan – name: Springer Nature B.V |
| References | Erbe, Collins, Shen (CR3) 1990; 27 Kerst, de Haas, van der Schoot (CR13) 1993; 82 Kim, Park, Suh (CR10) 2003; 19 Smith, Khatcheressian, Lyman (CR6) 2006; 24 Holmes, O’Shaughnessy, Vukelja (CR18) 2002; 20 Rouveix, Giroud, Levacher (CR5) 2001; 3 Welte, Gabrilove, Bronchud (CR12) 1996; 15 Ataergin, Arpaci, Turan (CR11) 2008; 83 Lyman (CR16) 2009; 7 Lyman, Dale, Friedberg (CR17) 2004; 22 Carulli (CR4) 1997; 82 Roilides, Walsh, Pizzo (CR2) 1991; 163 Pettengell, Aapro, Brusamolino (CR7) 2009; 29 Lyman, Lalla, Barron (CR22) 2009; 31 Balducci, Al-Halawani, Charu (CR14) 2007; 12 Siena, Piccart, Holmes (CR21) 2003; 10 Watts, Addison, Long (CR8) 1997; 98 Lieschke, Burgess (CR1) 1992; 327 Green, Koelbl, Baselga (CR19) 2003; 14 Dunn, Goa (CR9) 2000; 59 Pinto, Liu, Doan (CR20) 2007; 23 Crawford, Dale, Kuderer (CR15) 2008; 6 G Carulli (134_CR4) 1997; 82 B Rouveix (134_CR5) 2001; 3 GH Lyman (134_CR22) 2009; 31 GJ Lieschke (134_CR1) 1992; 327 DV Erbe (134_CR3) 1990; 27 GH Lyman (134_CR17) 2004; 22 134_CR19 IH Kim (134_CR10) 2003; 19 JM Kerst (134_CR13) 1993; 82 GH Lyman (134_CR16) 2009; 7 MJ Watts (134_CR8) 1997; 98 A Holmes (134_CR18) 2002; 20 L Balducci (134_CR14) 2007; 12 134_CR12 TJ Smith (134_CR6) 2006; 24 S Ataergin (134_CR11) 2008; 83 E Roilides (134_CR2) 1991; 163 CJ Dunn (134_CR9) 2000; 59 J Crawford (134_CR15) 2008; 6 L Pinto (134_CR20) 2007; 23 S Siena (134_CR21) 2003; 10 134_CR7 |
| References_xml | – volume: 82 start-page: 606 year: 1997 end-page: 616 ident: CR4 article-title: Effects of recombinant human granulocyte colony-stimulating factor administration on neutrophil phenotype and functions publication-title: Haematologica – volume: 7 start-page: 99 year: 2009 end-page: 108 ident: CR16 article-title: Impact of chemotherapy dose intensity on cancer patient outcomes publication-title: JNCCN – volume: 98 start-page: 474 year: 1997 end-page: 479 ident: CR8 article-title: Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers publication-title: Br J Haematol doi: 10.1046/j.1365-2141.1997.2393053.x – volume: 14 start-page: 29 year: 2003 end-page: 35 ident: CR19 article-title: A randomized doubleblind multicenter phase III study of fixed-dose single administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy publication-title: Ann Oncol – volume: 163 start-page: 579 year: 1991 end-page: 583 ident: CR2 article-title: Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils publication-title: J Infect Dis doi: 10.1093/infdis/163.3.579 – volume: 59 start-page: 681 year: 2000 end-page: 717 ident: CR9 article-title: Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings publication-title: Drugs doi: 10.2165/00003495-200059030-00017 – volume: 327 start-page: 28 year: 1992 end-page: 35 ident: CR1 article-title: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1) publication-title: N Eng J Med doi: 10.1056/NEJM199207023270106 – volume: 83 start-page: 644 year: 2008 end-page: 648 ident: CR11 article-title: Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation publication-title: Am J Hematol doi: 10.1002/ajh.21206 – volume: 6 start-page: 109 year: 2008 end-page: 118 ident: CR15 article-title: Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice publication-title: JNCCN – volume: 24 start-page: 3187 year: 2006 end-page: 3205 ident: CR6 article-title: 2006 update of recommendation for the use of white blood cell growth factors: an evidence-based clinical practice guideline publication-title: J Clin Oncol doi: 10.1200/JCO.2006.06.4451 – volume: 31 start-page: 1092 year: 2009 end-page: 1104 ident: CR22 article-title: Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States publication-title: Clin Ther doi: 10.1016/j.clinthera.2009.05.003 – volume: 20 start-page: 727 year: 2002 end-page: 731 ident: CR18 article-title: Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.20.3.727 – volume: 10 start-page: 715 year: 2003 end-page: 724 ident: CR21 article-title: A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II–IV breast cancer publication-title: Oncol Rep – volume: 19 start-page: 753 year: 2003 end-page: 759 ident: CR10 article-title: Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy publication-title: Curr Med Res Opinion doi: 10.1185/030079903125002531 – volume: 27 start-page: 57 year: 1990 end-page: 60 ident: CR3 article-title: The effect of cytokines on the expression and function of Fc receptors for IgG on human myeloid cells publication-title: Mol Immunol doi: 10.1016/0161-5890(90)90060-D – volume: 29 start-page: 491 year: 2009 end-page: 513 ident: CR7 article-title: Implications of the European Organisation for Research and Treatment of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care publication-title: Clin Drug Invest – volume: 82 start-page: 3265 year: 1993 end-page: 3272 ident: CR13 article-title: Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells publication-title: Blood – volume: 12 start-page: 1416 year: 2007 end-page: 1424 ident: CR14 article-title: Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim publication-title: Oncologist doi: 10.1634/theoncologist.12-12-1416 – volume: 22 start-page: 4302 year: 2004 end-page: 4311 ident: CR17 article-title: Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study publication-title: J Clin Oncol doi: 10.1200/JCO.2004.03.213 – volume: 15 start-page: 1907 year: 1996 end-page: 1929 ident: CR12 article-title: Filgrastim (r-metHuG-CSF): the first 10 years publication-title: Blood – volume: 23 start-page: 2283 year: 2007 end-page: 2295 ident: CR20 article-title: Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials publication-title: Curr Med Res Opin doi: 10.1185/030079907X219599 – volume: 3 start-page: 83 year: 2001 end-page: 89 ident: CR5 article-title: G-CSF: mode of action and antiinfective activities publication-title: Antibiotiques – volume: 82 start-page: 3265 year: 1993 ident: 134_CR13 publication-title: Blood doi: 10.1182/blood.V82.11.3265.3265 – ident: 134_CR12 doi: 10.1182/blood.V88.6.1907.bloodjournal8861907 – volume: 20 start-page: 727 year: 2002 ident: 134_CR18 publication-title: J Clin Oncol doi: 10.1200/JCO.20.3.727 – volume: 327 start-page: 28 year: 1992 ident: 134_CR1 publication-title: N Eng J Med doi: 10.1056/NEJM199207023270106 – volume: 98 start-page: 474 year: 1997 ident: 134_CR8 publication-title: Br J Haematol doi: 10.1046/j.1365-2141.1997.2393053.x – volume: 59 start-page: 681 year: 2000 ident: 134_CR9 publication-title: Drugs doi: 10.2165/00003495-200059030-00017 – volume: 6 start-page: 109 year: 2008 ident: 134_CR15 publication-title: JNCCN – volume: 3 start-page: 83 year: 2001 ident: 134_CR5 publication-title: Antibiotiques – volume: 24 start-page: 3187 year: 2006 ident: 134_CR6 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.06.4451 – volume: 7 start-page: 99 year: 2009 ident: 134_CR16 publication-title: JNCCN – volume: 19 start-page: 753 year: 2003 ident: 134_CR10 publication-title: Curr Med Res Opinion doi: 10.1185/030079903125002531 – ident: 134_CR7 doi: 10.2165/00044011-200929080-00001 – volume: 23 start-page: 2283 year: 2007 ident: 134_CR20 publication-title: Curr Med Res Opin doi: 10.1185/030079907X219599 – volume: 10 start-page: 715 year: 2003 ident: 134_CR21 publication-title: Oncol Rep – volume: 27 start-page: 57 year: 1990 ident: 134_CR3 publication-title: Mol Immunol doi: 10.1016/0161-5890(90)90060-D – volume: 22 start-page: 4302 year: 2004 ident: 134_CR17 publication-title: J Clin Oncol doi: 10.1200/JCO.2004.03.213 – volume: 163 start-page: 579 year: 1991 ident: 134_CR2 publication-title: J Infect Dis doi: 10.1093/infdis/163.3.579 – volume: 83 start-page: 644 year: 2008 ident: 134_CR11 publication-title: Am J Hematol doi: 10.1002/ajh.21206 – volume: 12 start-page: 1416 year: 2007 ident: 134_CR14 publication-title: Oncologist doi: 10.1634/theoncologist.12-12-1416 – volume: 31 start-page: 1092 year: 2009 ident: 134_CR22 publication-title: Clin Ther doi: 10.1016/j.clinthera.2009.05.003 – volume: 82 start-page: 606 year: 1997 ident: 134_CR4 publication-title: Haematologica – ident: 134_CR19 doi: 10.1093/annonc/mdg019 |
| SSID | ssj0017652 |
| Score | 1.9181848 |
| Snippet | Background
In order to analyze the clinical activity and cost-effectiveness of granulocyte colony-stimulating factors (G-CSF), the prophylactic usage of G-CSF... In order to analyze the clinical activity and cost-effectiveness of granulocyte colony-stimulating factors (G-CSF), the prophylactic usage of G-CSF in patients... |
| SourceID | proquest pubmed crossref springer nii |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 118 |
| SubjectTerms | Aged Antibiotics, Antineoplastic - therapeutic use Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Blood diseases Cancer Research Chemotherapy Cost-benefit Cost-Benefit Analysis Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Doxorubicin - administration & dosage Doxorubicin - adverse effects Drug Administration Schedule Drug dosages Drug therapy Febrile neutropenia (FN) Female Fever - blood Fever - drug therapy Granulocyte Colony-Stimulating Factor - administration & dosage Granulocyte Colony-Stimulating Factor - economics Granulocyte colony-stimulating factors (G-CSF) Health care expenditures Humans Lenograstim Leukocytes - drug effects Lymphoma Lymphoma, Large B-Cell, Diffuse - blood Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - economics Male Medicine Medicine & Public Health Middle Aged Neutropenia - blood Neutropenia - drug therapy Neutropenia - economics Neutrophils - drug effects Non-Hodgkin lymphoma (NHL) Oncology Original Article Prednisone - administration & dosage Prednisone - adverse effects R-CHOP Recombinant Proteins - administration & dosage Recombinant Proteins - economics Risk factors Surgical Oncology Vincristine - administration & dosage Vincristine - adverse effects |
| SummonAdditionalLinks | – databaseName: SpringerLink Journals (ICM) dbid: U2A link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Ja90wEBZtCqWX0HR104Q59NQi8CZZOobSEALtKQ9yM9ocHrzoldqG-N-0f6W_LDNeXlqaFnrxwZZkwcxovtFsjL1rgjNBS81z5TwvlTFcW2241WkIunD4Zozy_SLPVuX5pbic87jbJdp9cUmOJ_UvyW5ZSWGSFEhVlByB4yNBpjsy8So_2bkOKjm22aFCZVwjul9cmfct8ZsyehjX6_tw5h8-0lH1nD5l-zNmhJOJyAfsQYjP2OPPs1f8Ofuxougw2DZwhZqnR_U0dAGoHHUcOIrw9diiK17B1FwHArLvAPnP794MLaxbWNIjNwP0bWj6DZjocYG241O8Bx6JgOgWGrSg8RiBGPqObvHj2sCU6AiBKiXjnDEohPaC3HA9p3cNL9jq9NPFxzM-t17gSB3dcVVa6kRdyixURjuBmlQp7xuJdDXSkiGpVBZUkQmfC-VClaJhIgyaPzbzVhQv2V7cxvCaQUY9dqsm-KBkmTo8L7xyRWq9k1Yq6RKWLjSo3VyXnNpjbOq7ispEthp_WhPZ6puEvd9N-ToV5fjX4CMkLC5Nz0xUBSHKqkSYgpYvwq-EHS4kr2f5bWslqdS8LoqEwe4rCh55U0wM256GZDmCXSkS9mpilN1e8hStWkmTPyycc7f0Xzf65r9GH7In0_U2BRG9ZXvdtz4cIT7q7PEoD7dt5Agw priority: 102 providerName: Springer Nature |
| Title | Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy |
| URI | https://cir.nii.ac.jp/crid/1573105974853107584 https://link.springer.com/article/10.1007/s10147-010-0134-x https://www.ncbi.nlm.nih.gov/pubmed/20924633 https://www.proquest.com/docview/860452933 https://www.proquest.com/docview/861205765 |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZoKyEuiDehtJoDJ5BFnIfjnNBSbalAVAix0nKKHNupVtp6C0mk5t_wU5nJq0JAL1kpGyeWZjwPz-f5GHtVOaNdLnMeKWN5orTmeZlrXuahc3ls8E6P8j2XZ6vk4zpdj9iceoRVTjaxN9R2Z2iP_K2S1Pwb0-93Vz84kUZRcXVk0NhjB9S5jBBd2XrOt0Qme8IdalnGc4zzp6LmcHJOJIS5JFRWnPDrP9zSnt9s_hVx_lUt7Z3Q6QN2f4weYTGI-yG74_wjdvfzWB9_zH6tCCcGuwou0Ae16Ki6xgE1pvYdx8V82ZN1-QsYaHbAoSJ3EIHVXQ2bGqZzktsO2tpV7Ra0tzi-bvgA_EDbCBjmQoWpNNoT8K5taDvfbzQMJx7BUctkHNOjQ2gqqBaX4zmv7glbnS6_nZzxkYOBo5jyhqukJErqRAqX6dyk6FKVsraSKGAtS8oolRJOxSK1UaqMy0LMUFKNeVApbJnGT9m-33n3nIEgst2sctYpmYQGDYdVJg5La2QplTQBCycRFGZsUE48GdviprUySa3AjxYkteI6YK_nIVdDd47bHj5CueKr6SrSLKbQMkswXsEUGOOwgB1OEi_GhVwXs9oFDOZ_cQVSWUV7t2vpERFh1CvTgD0b9GSeSxRieitp8JtJcW5e_d-Jvrh1Iofs3rCvTeihl2y_-dm6IwyMmvK4V3-8qhNxzA4WH75_WuLv--X5l694dxUtfgM4LQ6E |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKVgIuiDehFOYAF5BFno5zQIhHqy1tVwh1pd6CYzvVSltvIYlo_g1_gP_ITB5bIaC3XvaQjZORZjz-JvP4GHteWq1sJjIeSm14LJXiWZEpXmS-tVmk8UpX5TsT03n86Tg53mC_xl4YKqscfWLnqM1K0zfy11LQ8G8Mv9-efeNEGkXJ1ZFBo7eKfdv-wIiterP3EdX7Igx3d44-TPlAKsDxvVnNZVwQx3IsApuqTCd4RkhpTClQYiUKCpGkDKyMgsSEidQ29RFyJwqBfRGYgkgi0ONvxhFGMhO2-X5n9vnLOm2Rio7ih4ak8QwjizGN2vfqBTFVeVIdWBTz8z8OwmtusfgXxv0rP9sde7u32a0Br8K73sDusA3r7rLrh0NG_h77OafKNFiVcIKnXoNHY1tboFHYruXoPk47ejB3Aj2xD1jcOi2EYFRbwaKCsTNz2UJT2bJZgnIG11c170tN0BsDAmsoMXhHDwbONjUlENxCQd9jCZaGNOOarh6FREFDPB06y9r7bH4lCnrAJm7l7CMGAdH7pqU1VorY1-iqjNSRXxgtCiGF9pg_qiDXw0h0YuZY5hfDnElrOb40J63l5x57uV5y1s8DuezmbdQrPpp-gySNCMymMSIkDLoR-Xlsa9R4PriOKl8busdg_S_ueUrkKGdXDd0ShIizReKxh72drGUJfQyoBS1-NRrOxaP_K-jjSwV5xm5Mjw4P8oO92f4Wu9l_VafapSdsUn9v7DbCsrp4OmwGYF-vev_9Bpz5Rss |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkSouiHdDKcwBLiCrcR6Oc0AIUVYthYoDK-0tOLZTrdR6C0lE82_4G_w7ZvLYCgG99bKH3Tg7yrwzj4-x55Uz2uUy55EylidKa56XueZlHjqXxwa_6bt8j-XBPPmwSBcb7Nc0C0NtlZNN7A21XRl6R76nJC3_xvR7rxq7Ij7vz96cf-MEIEWF1glNY5CQI9f9wOytfn24j6x-EUWz91_eHfARYIAjDXnDVVIS3nIihct0blL0F0pZW0mkXsuS0iWlhFOxSG2UKuOyEMPvVGOQXwpbEmAEWv-bWZwKUrFssc71RCZ7sB9al8ZzzDGmguowtScS6vekjrA44Rd_uMQbfrn8V7T7V6W2d4CzO-z2GLnC20HU7rIN5--xrU9jbf4--zmnHjVYVXCC_q9FJ9k1Dmgptu84GpKzHijMn8AA8QMOlaiDCKzualjWMM1onnbQ1g4fP2hv8Xzd8KHpBO0yYIgNFabxaMvAu7ahUoJfahimLcHRumY803emECkokmfjjFn3gM2vhT0P2aZfebfNQBDQb1Y565RMQoNGyyoTh6U1spRKmoCFEwsKMy5HJ4yO0-JyrTNxrcA_LYhrxUXAXq6PnA-bQa66eBf5iremT5FmMYW1WYKxEqbfGAMGbGfieDEakbpYi3zAYP0raj-VdLR3q5YuERFG3DIN2KNBTta0RCGm1pIOv5oE5_LW_yX08ZWEPGNbqHXFx8Pjox12a3i9Tk1MT9hm8711uxifNeXTXhOAfb1u1fsNachJmw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Usage+of+granulocyte+colony-stimulating+factor+every+2+days+is+clinically+useful+and+cost-effective+for+febrile+neutropenia+during+early+courses+of+chemotherapy&rft.jtitle=International+journal+of+clinical+oncology&rft.au=YAKUSHIJIN+Yoshihiro&rft.au=SHIKATA+Hisaharu&rft.au=TAKAOKA+Ikue&rft.au=HORIKAWA+Tamami&rft.date=2011-04-01&rft.issn=1341-9625&rft.volume=16&rft.issue=2&rft.spage=118&rft.epage=124&rft_id=info:doi/10.1007%2Fs10147-010-0134-x&rft.externalDocID=10029366407 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1341-9625&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1341-9625&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1341-9625&client=summon |